Of the compounds Nick sent me for testing, I identified CGP 57148B (also known as STI571, Gleevec, Glivec or imatinib mesylate) as the most effective at killing CML cells without harming normal ...

This overexpression suggested that imatinib could be clinically applicable in uveal melanoma metastases; this was tested in a group of patients who were assigned to receive imatinib 600 mg daily ...

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

The PhALLCON trial compared Iclusig (ponatinib) to imatinib – sold by Novartis as Glivec/Gleevec, but also available as a generic – on top of a reduced-intensity chemotherapy regimen in 230 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution ...

Find all the commercial and brand names of generic drug called Imatinib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

Longer-term data for Novartis Scemblix reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML: Basel Tuesday, December 10, ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key ...